Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Xeroderma pigmentosum (XP) is described in the packet's definition as a rare genodermatosis characterized by extreme sensitivity to ultraviolet (UV)-induced changes in the skin and eyes, and multiple skin cancers. The definition states that it is subdivided into eight complementation groups according to the affected gene: classical XP (groups A to G) and XP variant. According to GeneReviews, XP is an example of accelerated photoaging, with the sun-exposed skin of affected children resembling that of farmers and sailors after many years of extreme sun exposure.
GeneReviews estimates prevalence at about 1 in 1,000,000 in the United States and Europe, higher in certain populations, usually related to founder variants. It cites about 1 in 22,000 in Japan, and as high as about 1 in 10,000 in North Africa and the Middle East, especially in communities where consanguinity and endogamy are common. GeneReviews describes the mode of inheritance as autosomal recessive.
GeneReviews bases its clinical description on 106 individuals with XP examined at the National Institutes of Health from 1971 to 2009.
Skin. About 60 percent had an acute sunburn reaction on minimal UV exposure; the remainder tanned without excessive burning. Freckle-like lesions and dry skin with poikiloderma on sun-exposed skin were each reported in all individuals. Median onset of cutaneous symptoms is described as between ages one and two years, limited to sun-exposed areas, with premalignant actinic keratoses developing early. Cutaneous neoplasia was reported in about 65 percent.
Eyes. Ocular abnormalities were reported in about 90 percent, usually limited to the anterior, UV-exposed portions of the eyes beginning in the first decade of life. Findings include dry eyes, photophobia, severe keratitis, corneal opacification, benign conjunctival inflammatory masses, lid atrophy with ectropion or entropion, and lash loss. Epithelioma, squamous cell carcinoma and melanoma of UV-exposed eye portions are described as common.
Nervous system. Slowly worsening neurologic abnormalities were reported in approximately 25 percent. Onset may be early in infancy or delayed until the second decade or later. They may be mild, such as isolated hyporeflexia, or severe, including acquired microcephaly, progressive intellectual impairment, sensorineural hearing loss, spasticity, ataxia and seizures.
Other neoplasms. GeneReviews reports a 10- to 20-fold increase in other neoplasias, including brain and central nervous system tumors, hematologic malignancies, breast cancer, tumors of the female reproductive tract, papillary thyroid cancer and kidney cancer.
The packet lists no certified causative-gene entry for XP, so no specific genes are named here. The definition states only that the complementation groups are defined by the affected gene. According to GeneReviews, XP is inherited in an autosomal recessive manner, and the proportion of cases attributed to variants in a specific gene may vary by country of origin because of founder variants. GeneReviews states that no genotype-phenotype correlations beyond those in its tables have been identified, and describes cells from individuals with XP as hypersensitive to environmental mutagens in addition to UV radiation.
According to GeneReviews, the diagnosis of XP is established in a proband on the basis of clinical findings and family history and, or, identification of biallelic pathogenic variants in the genes listed in its chapter. Suggestive findings it lists include acute sun sensitivity with severe sunburn or blistering, marked freckle-like facial pigmentation before age two years, skin cancer within the first decade, photophobia with conjunctival injection, severe keratitis, lid changes, ocular surface neoplasms, diminished or absent deep tendon reflexes, progressive sensorineural hearing loss, acquired microcephaly, progressive cognitive impairment and ataxia. GeneReviews states that family history is consistent with autosomal recessive inheritance and that absence of a known family history does not preclude the diagnosis.
For molecular testing, GeneReviews describes a multigene panel and comprehensive genomic testing such as exome or genome sequencing, noting that gene-targeted testing requires a judgment about which genes are involved while genomic testing does not. Its differential diagnosis lists other nucleotide excision repair disorders with photosensitivity, including cerebrooculofacioskeletal syndrome, trichothiodystrophy, Cockayne syndrome, XP/Cockayne syndrome complex and UV-sensitive syndrome. The packet contains no newborn screening information.
The packet lists no active FDA-approved treatment record for XP. Its only orphan drug entry, a peptide sponsored by ProGeLife, has a withdrawn status and is not a current option; an orphan designation does not by itself indicate approval or active development.
GeneReviews describes management by manifestation. Premalignant lesions are described as treated by freezing with liquid nitrogen, and larger areas of sun-damaged skin by field treatments such as topical 5-fluorouracil or imiquimod. Cutaneous neoplasms are described as treated as in persons without XP, with Mohs micrographic surgery described as the preferred approach for recurrent skin cancers. For individuals with large numbers of new tumors, GeneReviews states that oral isotretinoin or acitretin can be effective in preventing new neoplasms after removal of existing cancers, with toxicities that include hepatic, hyperlipidemic and teratogenic effects. Metastatic melanoma and invasive squamous cell carcinoma are described as treated with systemic anti-PD1, anti-PDL-1 and BRAF inhibitor therapy, and hematologic malignancies with standard chemotherapy, with the note that bone marrow transplant has not been successful in XP. Eye-related options listed include surgery and topical agents for neoplasms, lubricating drops or soft contact lenses for corneal injury, and corneal transplantation for severe keratitis. Hearing aids, cochlear implants and hormone replacement therapy for premature menopause are also listed.
GeneReviews describes surveillance consisting of skin examination by a physician every 3 to 12 months depending on severity, caregiver skin examination at least weekly, eye examination at least every 6 months, audiograms every 6 to 12 months, annual neurologic examination for symptomatic persons, and annual laboratory assessment for premature ovarian insufficiency beginning at age 18 years. It also names UV exposure from sunlight and artificial sources, and cigarette smoke, as agents of concern.
2 trials found
The packet contains no certified natural history field for XP. The GeneReviews clinical description states that the neurologic abnormalities worsen slowly in the approximately 25 percent of individuals in whom they were reported, and that the frequency and extent of cutaneous neoplastic lesions depend on the amount of UV exposure. Beyond these statements, prognosis is not certified in this packet.
The packet certifies active clinical research for XP, including a recruiting natural history study of DNA repair disorders sponsored by an academic institution. Its research literature digest describes the publication landscape as dominated by basic science and preclinical work. Active clinical trials for this condition are listed on ClinicalTrials.gov.
Data assembled from 6 of 12 sources · Last updated Nov 17, 2026, 1:46 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning xeroderma pigmentosum
Updated Jun 5, 2026
A qualitative study highlights the psychosocial challenges faced by families of children with xeroderma pigmentosum. The research underscores the emotional and social impacts of this rare skin disorder on affected families.
A recent study reviews five cases of central nervous system tumors in patients with xeroderma pigmentosum, contributing to the understanding of this rare disease's complications. The findings highlight the need for increased surveillance and research into the mechanisms linking xeroderma pigmentosum and tumor development.